Calluna Pharma Completes Enrollment in Phase 2 AURORA Study of CAL101 for Idiopathic Pulmonary Fibrosis (IPF)
Study of CAL101, which targets a novel upstream pathway implicated in fibrotic disease, enrolls 161 patients more than six months ahead of plan; topline data expected Q1 2027 Drug candidate, a monoclonal antibody which targets S100A4, a novel upstream pathway implicated in fibrotic disease, aims to preserve lung function in IPF patients OSLO, Norway & … [Read more…]
